CAS: 1186206-79-0; N-(5-((4-((4-Ethylpiperazin-1-yl)Methyl)-3-(Trifluoromethyl)Phenyl)Carbamoyl)-2-Methylphenyl)-5-(Thiophen-2-yl)Nicotinamide
- 英文名称N-(5-((4-((4-Ethylpiperazin-1-yl)Methyl)-3-(Trifluoromethyl)Phenyl)Carbamoyl)-2-Methylphenyl)-5-(Thiophen-2-yl)Nicotinamide
- 中文名称N-[4-[(4-乙基-1-哌嗪基)甲基]-3-(三氟甲基)苯基]-4-甲基-3-[[[5-(2-噻吩基)-3-吡啶基]羰基]氨基]苯甲酰胺
- IUPAC名称N-(5-((4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)-2-methylphenyl)-5-(thiophen-2-yl)nicotinamide
- CAS编号1186206-79-0
- MFCD编号:MFCD25372028
- 分子式:C32H32F3N5O2S分子量:607.7
- 产品CID: 241746
- 产品分类生物化工 → 抑制剂 → 蛋白酪氨酸激酶
物理性质
- 沸点612.3±55.0 °C(预测)
- 密度1.321±0.06 g/cm3(预测)
- pKa:11.66±0.70(预测)
- PSA:112.79
- LogP:7.4232
- 溶解性≥60.8 mg/mL In Etoh; Insoluble In H2O; ≥102 mg/mL In DMSO
- 外观形态白色至淡黄色粉末
- 储存条件储存在 -20°C
- 产品应用该化合物是一种在抗抗性癌症的EGFR-MUTANT,抗性亚氨基酶抑制剂(TKI)中示范活动的强力小分子EPH受体强抗体强力激素性激素抑制剂,在体外,ALW-2-41-47显著降低了抗性肿瘤细胞细胞细胞存活和扩散能力,如ERLOTINIB和OSIMERTINIB(AZD9291)等第一代EGPHA2依赖信号的抑制剂.在VIVO,AL W-II-41-27明显抑制抗性肺癌抗性细胞模型的肿瘤增长,强调其克服已获得的抗性机制的潜力.ALW-41-27利用替代受体抗体抗性动力性动力抑制器的路径,为治疗耐性癌症提供了很有希望的战略.这些发现支持将它用作研究血管信号,抗力生物学和肿瘤定向疗法的宝贵研究复合物.
上下游产品
3-amino-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide 5-(thiophen-2-yl)nicotinic acid 4-amino-2-(trifluoromethyl)benzaldehyde 4-(4-ethylpiperazin-1-ylmethyl)-3-trifluoromethylphenylamine合成工艺路线路线简述
📜4-氨基-2-三氟甲基苯甲腈置于盐酸,4-二甲氨基吡啶,Palladium On Activated Charcoal,氢气,二异丁基氢化铝,N,N-二异丙基乙胺,Methanaminium,N-[(Dimethylamino)(3H-1,2,3-Triazolo[4,5-B]Pyridin-3-Yloxy)Methylene]-N-Methyl-,Hexafluorophosphate(1-)体系中,用 四氢呋喃,甲醇,二氯甲烷,水,乙酸乙酯,甲苯 用作溶剂,化学反应 75.08H,反应生成N-[4-[(4-乙基-1-哌嗪基)甲基]-3-(三氟甲基)苯基]-4-甲基-3-[[[5-(2-噻吩基)-3-吡啶基]羰基]氨基]苯甲酰胺
参考文献:A Putative Single-Photon Emission Ct Imaging Tracer For Erythropoietin-Producing Hepatocellular A2 Receptor
标题:A Putative Single-Photon Emission Ct Imaging Tracer For Erythropoietin-Producing Hepatocellular A2 Receptor
摘要:
Doi:10.1021/acsmedchemlett.1C00030
海关参考信息
- 2912110000-甲醛
2912210000-苯甲醛
2921211000-乙二胺
2933310010-吡啶 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Li X, Li D, Ma R. ALW-II-41-27, an EphA2 inhibitor, inhibits proliferation, migration and invasion of cervical cancer cells via inhibition of the RhoA/ROCK pathway. Oncol Lett. 2022 Apr;23(4):129. doi: 10.3892/ol.2022.13249. Epub 2022 Feb 18.
2: Zeng L, Li K, Wei H, Hu J, Jiao L, Yu S, Xiong Y. A Novel EphA2 Inhibitor Exerts Beneficial Effects in PI-IBS in Vivo and in Vitro Models via Nrf2 and NF-κB Signaling Pathways. Front Pharmacol. 2018 Mar 27;9:272. doi: 10.3389/fphar.2018.00272.
3: Moccia M, Liu Q, Guida T, Federico G, Brescia A, Zhao Z, Choi HG, Deng X, Tan L, Wang J, Billaud M, Gray NS, Carlomagno F, Santoro M. Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase. PLoS One. 2015 Jun 5;10(6):e0128364. doi: 10.1371/journal.pone.0128364.
合成参考文献
参考文献:10.1124/mol.119.115964
摘要:Lee TD, Lee OW, Brimacombe KR, Chen L, Guha R, Lusvarghi S, Tebase BG, Klumpp-Thomas C, Robey RW, Ambudkar SV, Shen M, Gottesman MM, Hall MD. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular Pharmacology. 2019 Nov;96(5):629–40. doi: 10.1124/mol.119.115964.
📝 需求与反馈
尽可能描述清楚需求与问题信息
